加拿大 - 英文 - Health Canada

eugia pharma inc. - busulfan - solution - 60mg - busulfan 60mg

加拿大 - 英文 - Health Canada

marcan pharmaceuticals inc - busulfan - solution - 60mg - busulfan 60mg - antineoplastic agents

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - busulfan - tablet - 2mg

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - busulfan -

马耳他 - 英文 - Malta Medicines Authority

central procurement & supplies unit - busulfan - film-coated tablet - busulfan 2 milligram(s) - antineoplastic agents

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - busulfan, quantity: 60 mg - injection - excipient ingredients: dimethylacetamide; macrogol 400 - busulfex is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - busulfan, quantity: 60 mg - injection, solution - excipient ingredients: dimethylacetamide; macrogol 400 - busulfan injection is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - busulfan, quantity: 60 mg - injection, solution - excipient ingredients: macrogol 400; dimethylacetamide - busulfan injection is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - busulfan, quantity: 2 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; lactose; titanium dioxide; hypromellose; triacetin - indications as at 10 february 2005: treatment of chronic granulocytic leukaemia. it has been shown to be superior to splenic irradiation when judged by survival times, control of spleen size and maintenance of haemoglobin levels. although not curative, busulfan reduces the total granulocyte mass, relieves disease symptoms and improves the clinical state of the patient. busulfan is not useful once blast transformation has occurred. busulfan produces prolonged remission in polycythaemia vera. it is especially useful in cases resistant to radiophosphorus (32 p) and where there is marked thrombocytosis. busulfan is useful in selected cases of essential thrombocythaemia and myelofibrosis.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - busulfan, quantity: 60 mg - injection, concentrated - excipient ingredients: dimethylacetamide; macrogol 400 - busulfan intas is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.